ISSN 2348-0319 International Journal of Innovative and Applied Research [2024]
(Volume 12, Issue 03)
59-69

Journal home page: http://www.journalijiar.com

INTERNATIONAL JOURNAL
OF INNOVATIVE AND APPLIED RESEARCH

REVIEW ARTICLE

Article DOI: 10.58538/IJIAR/2090
DOI URL: *http://dx.doi.org/10.58538/IJIAR/2090*

ANTIRETROVIRAL THERAPY AND PLATELET ABERRATIONS: A REVIEW IN HIV PATIENTS

Emmanuel Ifeanyi Obeagu[1] and Getrude Uzoma Obeagu[2]

1. Department of Medical Laboratory Science, Kampala International University, Ishaka, Uganda.
2. School of Nursing Science, Kampala International University, Ishaka, Uganda.

Manuscript Info

Manuscript History
Received: 25 February 2024
Final Accepted: 27 March 2024
Published: March 2024

Keywords:
Antiretroviral Therapy, Platelets, Thrombocytopenia, HIV, Immune Reconstitution Inflammatory Syndrome, Coagulation Disorders

Abstract

Antiretroviral therapy (ART) has revolutionized the management of human immunodeficiency virus (HIV) infection, significantly reducing morbidity and mortality rates worldwide. However, emerging evidence suggests that ART may be associated with alterations in platelet function and homeostasis, leading to platelet aberrations such as thrombocytopenia and platelet hyperactivity in HIV patients. This review provides a comprehensive overview of the relationship between ART and platelet aberrations in HIV-infected individuals. We discuss the epidemiology, pathogenesis, clinical manifestations, and management strategies of platelet abnormalities associated with ART, including immune reconstitution inflammatory syndrome (IRIS)-related thrombocytopenia and ART-induced coagulation disorders. Furthermore, we explore potential mechanisms underlying ART-induced platelet aberrations, including direct drug toxicity, immune-mediated mechanisms, and viral factors. Understanding the impact of ART on platelet function and homeostasis is essential for optimizing the management of HIV-infected individuals and minimizing the risk of associated complications.

***Corresponding Author:-** **Emmanuel Ifeanyi Obeagu,** Department of Medical Laboratory Science, Kampala International University, Ishaka, Uganda.

Introduction:-

Antiretroviral therapy (ART) stands as the cornerstone of HIV management, significantly altering the landscape of the HIV/AIDS pandemic by suppressing viral replication, restoring immune function, and improving patient outcomes. However, as ART becomes increasingly widespread, attention has turned to its potential effects on various physiological systems beyond viral control. Among these, platelet function has emerged as a subject of interest, with accumulating evidence suggesting that ART may influence platelet homeostasis in HIV-infected individuals. Platelets play a crucial role in hemostasis, inflammation, and immune regulation, functioning not only as primary mediators of coagulation but also as key modulators of immune responses. Perturbations in platelet function, characterized by alterations in platelet count, activity, or reactivity, have been implicated in the pathogenesis of numerous diseases, including cardiovascular disorders, immune-mediated conditions, and infectious diseases. In the context of HIV infection, platelet aberrations have long been recognized, with thrombocytopenia being a common hematological complication, particularly in advanced disease stages. However, the introduction of ART has brought about new complexities in the relationship between HIV, ART, and platelets. While ART has been

associated with improvements in platelet counts in some cases, emerging evidence suggests that certain ART regimens may also contribute to platelet dysfunction, thrombocytopenia, and thrombotic events, posing challenges to the management of HIV-infected individuals.[1-28]

Understanding the epidemiology, pathogenesis, and clinical implications of platelet aberrations in the context of ART is of paramount importance for optimizing patient care and minimizing the risk of associated complications. This review aims to provide a comprehensive overview of the relationship between ART and platelet function in HIV-infected individuals, shedding light on the mechanisms underlying ART-induced platelet abnormalities and discussing strategies for their management and prevention. By elucidating the complex interplay between ART and platelet homeostasis, we hope to inform clinical practice and guide future research efforts aimed at optimizing the care of HIV-infected individuals in the era of ART.

Epidemiology and Clinical Manifestations of Platelet Aberrations in HIV Patients Receiving ART

Thrombocytopenia, characterized by a reduction in platelet count below normal levels, is a well-documented hematological complication in HIV-infected individuals, particularly in advanced disease stages. However, the introduction of antiretroviral therapy (ART) has led to shifts in the epidemiology and clinical manifestations of platelet aberrations in this population. While ART has been associated with improvements in platelet counts in some cases, thrombocytopenia remains a significant concern, affecting approximately 5-40% of HIV patients on ART, depending on the population studied and the definition used. The clinical manifestations of thrombocytopenia in HIV patients receiving ART can vary widely, ranging from asymptomatic mild thrombocytopenia to severe bleeding events, such as petechiae, purpura, and mucosal bleeding. Importantly, the risk of bleeding complications is not solely determined by platelet count but also by other factors, including platelet function, the presence of comorbidities (such as liver disease or renal insufficiency), and concurrent medication use (such as nonsteroidal anti-inflammatory drugs or antiplatelet agents).[29-55]

Platelet hyperactivity, characterized by increased platelet activation and aggregation, has also been observed in HIV-infected individuals on ART, particularly in the setting of immune activation and inflammation. Platelet hyperactivity may contribute to the pathogenesis of thrombotic events, such as myocardial infarction, stroke, and venous thromboembolism, which represent significant causes of morbidity and mortality in HIV-infected individuals. Furthermore, platelet hyperactivity may promote endothelial dysfunction and vascular inflammation, exacerbating the risk of cardiovascular complications in this population. Beyond thrombocytopenia and platelet hyperactivity, HIV-infected individuals on ART may also experience other platelet-related abnormalities, such as qualitative defects in platelet function, altered platelet turnover kinetics, and immune-mediated platelet destruction. These abnormalities can manifest clinically as a range of hematological and non-hematological complications, including immune thrombocytopenic purpura (ITP), drug-induced thrombocytopenia, and thrombotic microangiopathy (TMA).[56-80]

Pathogenesis of Platelet Aberrations Associated with ART

The pathogenesis of platelet aberrations in HIV-infected individuals receiving antiretroviral therapy (ART) is multifactorial, involving a complex interplay of viral, host, and treatment-related factors. Several mechanisms have been proposed to underlie the development of platelet abnormalities in this population, including direct drug toxicity, immune-mediated mechanisms, and viral factors. Certain antiretroviral drugs, particularly those belonging to the nucleoside reverse transcriptase inhibitor (NRTI) class, have been implicated in the development of platelet abnormalities. For example, zidovudine (AZT), a commonly used NRTI, has been associated with bone marrow suppression, including thrombocytopenia, through its myelosuppressive effects. Similarly, other NRTIs, such as didanosine (ddI) and stavudine (d4T), have been linked to mitochondrial toxicity, which can lead to peripheral neuropathy and bone marrow suppression, including thrombocytopenia. Immune dysregulation and inflammatory processes associated with HIV infection and ART may contribute to platelet aberrations through various immune-mediated mechanisms. Chronic immune activation and inflammation can lead to the production of proinflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), which can suppress megakaryopoiesis, the process by which platelets are produced in the bone marrow, and promote platelet destruction. Additionally, autoimmune phenomena, such as immune thrombocytopenic purpura (ITP), may occur as a result of immune reconstitution or immune reconstitution inflammatory syndrome (IRIS) following initiation of ART.[81-99]

HIV itself may directly affect platelet function and homeostasis through various viral factors and mechanisms. HIV infection can induce endothelial dysfunction and vascular inflammation, leading to platelet activation and aggregation. Furthermore, HIV viral proteins, such as the transactivator of transcription (Tat) protein and the envelope glycoprotein gp120, have been shown to interact with platelets and endothelial cells, promoting platelet activation and thrombus formation. Additionally, HIV-induced immune dysfunction and dysregulation may impair the host immune response against platelet antigens, leading to autoimmune-mediated platelet destruction. In addition to direct drug toxicity, immune-mediated mechanisms, and viral factors, other contributing factors may play a role in the pathogenesis of platelet aberrations in HIV-infected individuals receiving ART. These factors include comorbidities such as liver disease and renal insufficiency, which can affect platelet function and homeostasis, as well as concurrent medication use, such as nonsteroidal anti-inflammatory drugs (NSAIDs) or antiplatelet agents, which may increase the risk of bleeding complications.[100-119]

Mechanisms Underlying ART-Induced Platelet Dysfunction

The use of antiretroviral therapy (ART) in the management of HIV infection has been associated with various hematological complications, including platelet dysfunction. Several mechanisms have been proposed to underlie ART-induced platelet dysfunction, which can manifest as alterations in platelet function, reactivity, and homeostasis. Understanding these mechanisms is crucial for elucidating the pathogenesis of platelet dysfunction in HIV-infected individuals receiving ART. The following are key mechanisms underlying ART-induced platelet dysfunction: Certain antiretroviral drugs, particularly nucleoside reverse transcriptase inhibitors (NRTIs), have been implicated in directly affecting platelet function and viability. For example, zidovudine (AZT), a commonly used NRTI, has been associated with mitochondrial toxicity and oxidative stress, which can impair platelet function and viability. Similarly, other NRTIs, such as didanosine (ddI) and stavudine (d4T), have been shown to induce mitochondrial dysfunction in platelets, leading to impaired platelet aggregation and secretion. Immune dysregulation and inflammatory processes associated with HIV infection and ART may contribute to platelet dysfunction through immune-mediated mechanisms. Chronic immune activation and inflammation can lead to the production of proinflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), which can alter platelet function and reactivity. Additionally, immune reconstitution following initiation of ART may trigger immune-mediated platelet destruction, leading to thrombocytopenia and platelet dysfunction.[120-122]

HIV infection and ART can induce endothelial dysfunction, characterized by impaired endothelial cell function and increased expression of adhesion molecules and proinflammatory cytokines.[123] Endothelial dysfunction can promote platelet activation and aggregation through various mechanisms, including enhanced adhesion to endothelial cells, increased release of von Willebrand factor (vWF) and tissue factor, and dysregulation of nitric oxide (NO) signaling pathways. Furthermore, ART-induced endothelial dysfunction may exacerbate platelet dysfunction and contribute to the pathogenesis of thrombotic complications in HIV-infected individuals. HIV viral proteins, such as the transactivator of transcription (Tat) protein and the envelope glycoprotein gp120, have been shown to interact with platelets and endothelial cells, leading to platelet activation and thrombus formation. Tat protein can induce platelet activation and secretion of proinflammatory cytokines, while gp120 can promote platelet adhesion and aggregation through interactions with platelet surface receptors. These interactions between HIV viral proteins and platelets may contribute to the pathogenesis of platelet dysfunction in HIV-infected individuals receiving ART.

Management Strategies for Platelet Aberrations in HIV Patients on ART

The management of platelet aberrations in HIV-infected individuals receiving antiretroviral therapy (ART) requires a comprehensive approach aimed at addressing underlying causes, preventing complications, and optimizing patient outcomes.[124] Several strategies can be employed to manage platelet abnormalities in this population, including monitoring, pharmacological interventions, and supportive measures. Regular monitoring of platelet counts and function is essential for identifying platelet abnormalities and assessing the risk of bleeding or thrombotic complications in HIV-infected individuals receiving ART. Platelet counts should be monitored at baseline and periodically thereafter, with close attention to changes in platelet count over time. Additionally, assessment of platelet function using laboratory tests, such as platelet aggregation studies or flow cytometry, may be indicated in certain cases to further evaluate platelet abnormalities. Pharmacological interventions may be necessary to manage platelet aberrations and prevent complications in HIV patients on ART. Thrombocytopenia, characterized by a reduction in platelet count, may require treatment with platelet transfusions or pharmacological agents, such as corticosteroids or intravenous immunoglobulin (IVIG), in cases of severe or symptomatic thrombocytopenia. Additionally, the use of medications that affect platelet function, such as nonsteroidal anti-inflammatory drugs

(NSAIDs) or antiplatelet agents, should be carefully considered and monitored in HIV-infected individuals with platelet dysfunction.[125]

Addressing underlying causes of platelet aberrations, such as HIV infection, opportunistic infections, or drug toxicity, is essential for effective management.[125] Optimizing ART regimens to minimize adverse effects on platelet function and homeostasis may be necessary in cases where specific antiretroviral drugs are implicated in platelet abnormalities. Additionally, management of comorbidities, such as liver disease or renal insufficiency, which can affect platelet function and homeostasis, should be prioritized. Implementing preventive measures to reduce the risk of bleeding or thrombotic complications is important in HIV-infected individuals with platelet aberrations. This may include avoidance of activities or medications that increase the risk of bleeding, such as strenuous physical activity or anticoagulant therapy, in individuals with thrombocytopenia. Additionally, education and counseling regarding the signs and symptoms of bleeding or thrombotic events and appropriate management strategies should be provided to patients and healthcare providers. The management of platelet aberrations in HIV-infected individuals on ART often requires a multidisciplinary approach involving hematologists, infectious disease specialists, pharmacists, and other healthcare providers. Collaboration between healthcare providers is essential for coordinating care, optimizing treatment strategies, and addressing the diverse needs of HIV patients with platelet abnormalities.

Conclusion:-

Platelet aberrations represent a significant clinical concern in HIV-infected individuals receiving antiretroviral therapy (ART), with thrombocytopenia, platelet hyperactivity, and other platelet-related abnormalities contributing to a spectrum of hematological and non-hematological complications. Effective management of platelet aberrations requires a multifaceted approach that addresses underlying causes, prevents complications, and optimizes patient outcomes. Regular monitoring of platelet counts and function is essential for identifying platelet abnormalities and assessing the risk of bleeding or thrombotic complications in HIV-infected individuals on ART. Pharmacological interventions, such as platelet transfusions, corticosteroids, or immunoglobulin therapy, may be necessary to manage severe or symptomatic thrombocytopenia. Additionally, optimizing ART regimens to minimize adverse effects on platelet function and homeostasis is crucial for reducing the risk of platelet abnormalities in this population.

Preventive measures, including avoidance of activities or medications that increase the risk of bleeding, education and counseling regarding bleeding or thrombotic events, and a multidisciplinary approach involving healthcare providers from various specialties, are essential components of effective management strategies for platelet aberrations in HIV-infected individuals on ART.

References:-

1. Joseph J, Sandel G, Kulkarni R, Alatrash R, Herrera BB, Jain P. Antibody and Cell-Based Therapies against Virus-Induced Cancers in the Context of HIV/AIDS. Pathogens. 2023;13(1):14.
2. Thomford NE, Dzobo K, Chimusa E, Andrae-Marobela K, Chirikure S, Wonkam A, Dandara C. Personalized herbal medicine? A roadmap for convergence of herbal and precision medicine biomarker innovations. OMICS: A Journal of Integrative Biology. 2018;22(6):375-391.
3. Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. Elite Journal of HIV. 2024;2(1):16-30.
4. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. Madonna University journal of Medicine and Health Sciences. 2022;2(3):120-127.
5. Obeagu EI, Alum EU, Obeagu GU. Factors associated with prevalence of HIV among youths: A review of Africa perspective. Madonna University journal of Medicine and Health Sciences. 2023;3(1):13-18.https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/93.
6. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023 ;3(1):7-12.https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91.
7. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. J Pub Health Nutri. 2023; 6 (2). 2023; 141:1-2.links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf.

8. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
9. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. Int J Curr Res Med Sci. 2017;3(1): 21-38.DOI: 10.22192/ijcrms.2017.03.01.004
10. Obeagu EI, Obeagu GU, Musiimenta E, Bot YS, Hassan AO. Factors contributing to low utilization of HIV counseling and testing services. Int. J. Curr. Res. Med. Sci. 2023;9(2): 1-5.DOI: 10.22192/ijcrms.2023.09.02.001
11. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;129.links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf.
12. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
13. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
14. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. Journal of Pharmaceutical Research International. 2020;32(22):101-119.
15. Obeagu EI, Eze VU, Alaeboh EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J BioInnovation. 2016; 5:464-471.links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf.
16. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-916.https://www.academia.edu/download/38320140/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma2.EMMA1.pdf.
17. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. Int. J. Adv. Res. Biol. Sci. 2016;3(10): 55-65.DOI; 10.22192/ijarbs.2016.03.10.009
18. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75.links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf
19. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University journal of Medicine and Health Sciences. 2022;2(3):110-119.
20. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30.links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf.
21. Igwe CM, Obeagu IE, Ogbuabor OA. Clinical characteristics of people living with HIV/AIDS on ART in 2014 at tertiary health institutions in Enugu, Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;130.links/645a166f5762c95ac3817d32/Clinical-characteristics-of-people-living-with-HIV-AIDS-on-ART-in-2014-at-tertiary-health-institutions-in-Enugu.pdf.
22. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144.https://www.academia.edu/download/38320159/Obeagu_Emmanuel_Ifeanyi3__et_al.IJCRAR.pdf.
23. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-

4.links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf
24. Obeagu EI, Obeagu GU. Platelet-Driven Modulation of HIV: Unraveling Interactions and Implications. Journal home page: http://www. journalijiar. com.;12(01).
25. Obeagu EI, Obeagu GU. Studies on platlets diagnostic indexes in patients with acute myeloid leukaemia in Uganda. Int. J. Curr. Res. Med. Sci. 2023;9(1):24-27.
26. Obeagu EI, Okechukwu PU, Alum EU, Obeagu GU, Opoku D, Scott GY, Amekpor F. Platelets as actors in inflammation and immunity: A fulcrum in immunity. Int. J. Adv. Res. Biol. Sci. 2023;10(3):81-89.
27. Obeagu EI, Mbabazi A, Obeagu GU, Muhimbura E, Igwe MC, Owunna TA, Okafor CJ, Jakheng SP. Evaluation of Platelets and Some Inflammation Markers of Patients with Acute Myeloid Leukaemia In A Tertiary Hospital In Uganda. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2022;2(3):78-84.
28. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
29. Ifeanyi OE, Favour AA, Prayer NN. Updates on Human Immunodeficiency Virus and Platelets. Int. J. Adv. Res. Biol. Sci. 2020;7(6):1-7.
30. Obeagu EI, Muhimbura E, Kagenderezo BP, Nakyeyune S, Obeagu GU. An Insight of Interleukin-6 and Fibrinogen: In Regulating the Immune System. J Biomed Sci. 2022;11(10):83.
31. Okoroiwu IL, Obeagu EI, Vivian Egwim V. Assessment of White Blood Cell Count and Platelet Count in Women on Hormonal Contraceptives in Owerri, Imo State, Nigeria. J Res Med Dent Sci. 2021;9(12):498-501.
32. Obeagu EI, Okoroiwu IL, Obeagu GU. Relationship between Thrombopoietin and Interleukin 3: A Review. Int J Curr Res Chem Pharm. Sci. 2022;9(1):7-13.
33. Ukonu UC, Nwosu DC, Okoroiwu LI, Dike-Ndudim JN, Ukonu GO, Obeagu EI. Evaluation of Alloantibodies to human platelet antigen and Leucocyte antigen class 1 in Multitransfused patients in Owerri, Imo state. Int. J. Curr. Res. Med. Sci. 2023;9(1):38-44.
34. Obeagu EI. Gestational Thrombocytopaenia. J Gynecol Women's Health. 2023;25(3):556163.
35. Okoroiwu IL, Obeagu EI, Obeagu GU. Determination of clot retraction in preganant women attending antenatal clinic in federal medical centre Owerri, Nigeria. Madonna University Journal of Medicine and Health Sciences. 2022;2(2):91-97.
36. Ezimah AC, Obeagu EI, Asur A, Ezimah UA, Ezimah CO. Absolute platelet count in adult patients with musculoskeletal pain: Current perspectives. Int. J. Curr. Res. Med. Sci. 2016;2(2):30-7.
37. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005
38. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.
39. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139.links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf.
40. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. Madonna University journal of Medicine and Health Sciences. 2022;2(3):128-134.https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86.
41. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International. 2022:29-34.
42. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical Research International. 2020;32(24):9-18.
43. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137.links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf.
44. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. Int. J. Adv. Res. Biol. Sci. 2023;10(9):135-142.DOI: 10.22192/ijarbs.2023.10.09.015 links/6516faa61e2386049de5e828/A-Review-of-

knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf

45. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. Int. J. Adv. Res. Biol. Sci. 2023;10(9):128-134.DOI: 10.22192/ijarbs.2023.10.09.014 links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf.
46. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfected with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2017;3(5):100-104.DOI: 10.22192/ijcrms.2017.03.05.014 https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf
47. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. South Asian Journal of Research in Microbiology. 2022;13(2):26-31.
48. Viola N, Kimono E, Nuruh N, Obeagu EI. Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. Asian Journal of Dental and Health Sciences. 2023;3(2):7-14.http://ajdhs.com/index.php/journal/article/view/39.
49. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. J Clin Commun Med. 2020;2(3):180-183.DOI:**DOI:** 10.32474/JCCM.2020.02.000137links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf.
50. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. Journal of Pharmaceutical Research International. 2021;33(47A):78-84.
51. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth. 2023 Jul 29;6(1):203-211.http://research.sdpublishers.net/id/eprint/2819/.
52. Igwe MC, Obeagu EI, Ogbuabor AO, Eze GC, Ikpenwa JN, Eze-Steven PE. Socio-Demographic Variables of People Living with HIV/AIDS Initiated on ART in 2014 at Tertiary Health Institution in Enugu State. Asian Journal of Research in Infectious Diseases. 2022;10(4):1-7.
53. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. Journal of Pharmaceutical Research International. 2021;33(57A):360-368.
54. Igwe MC, Obeagu EI, Ogbuabor AO. ANALYSIS OF THE FACTORS AND PREDICTORS OF ADHERENCE TO HEALTHCARE OF PEOPLE LIVING WITH HIV/AIDS IN TERTIARY HEALTH INSTITUTIONS IN ENUGU STATE. Madonna University journal of Medicine and Health Sciences. 2022;2(3):42-57.https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/75.
55. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University journal of Medicine and Health Sciences. 2022;2(3):6-15.https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69
56. Obeagu EI, Ogunnaya FU. Pregnancyinduced Haematological Changes: A Key to Maternal and Child Health. European Journal of Biomedical. 2023;10(8):42-43.
57. Obeagu EI, Chikelu IM, Obarezi TN, Ogbuabor BN, Anaebo QB. Haematological effects of fluted pumpkin (Telfairia occidentalis) leaves in rats. International Journal of Life Sciences Biotechnology and Pharma Research. 2014;3(1):172-182.
58. Alum EU, Ugwu OP, Aja PM, Obeagu EI, Inya JE, Onyeije AP, Agu E, Awuchi CG. Restorative effects of ethanolic leaf extract of Datura stramonium against methotrexate-induced hematological impairments. Cogent Food & Agriculture. 2023;9(1):2258774.
59. Igwe MC, Obeagu EI. Determination of the Effect of Methanol Extract of Tetrapleura Tetraptera Fruit Osmotic Fragility of Erythrocytes, Platelet Aggregation and Phospholipase A2 Activity. Ann. Clin. Lab. Res. 2018; 6:250-255.

60. Obeagu EF, Onyenweaku FC, Nwobodo HA, Ochei KC, Ochiabuto Ogochukwu MT, Onwuasoanya UF. Impact of HIV and hepatitis b virus coinfection on selected haematological markers of the patients in Umuahia, Abia State, Nigeria. Ann Clin Lab Res. 2017;5(2):175.
61. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE.European Journal of Pharmaceutical and Medical Research, 2023;10(8): 564-568
62. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETRQVIRAL THERAPY.World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4(3): 153-160**.** links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETRQVIRAL-THERAPY.pdf.
63. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. Int. J. Curr. Res. Biosci. Plant Biol. 2015;2(4):45-49.
64. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. Int. J. Curr. Res. Chem. Pharm. Sci. 2019;6(12):45-8.DOI: 10.22192/ijcrcps.2019.06.12.004 links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf.
65. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. Int. J. Curr. Res. Med. Sci. 2023;9(2):6-13.DOI: 10.22192/ijcrms.2023.09.02.002 links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf.
66. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2016;2(4):29-33.links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf.
67. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. Int. J. Curr. Microbiol. App. Sci. 2015;4(4):906-910.https://www.academia.edu/download/38320134/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma.EMMA2.pdf.
68. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. Int. J. Curr. Res. Biol. Med. 2016;1(2):1-5.
69. Alum EU, Ugwu OP, Obeagu EI, Okon MB. Curtailing HIV/AIDS Spread: Impact of Religious Leaders. Newport International Journal of Research in Medical Sciences (NIJRMS). 2023;3(2):28-31.
70. Obeagu EI, Obeagu GU, Paul-Chima UO. Stigma Associated With HIV. AIDS: A Review. Newport International Journal of Public Health and Pharmacy (NIJPP). 2023;3(2):64-67.
71. Alum EU, Obeagu EI, Ugwu OP, Aja PM, Okon MB. HIV Infection and Cardiovascular diseases: The obnoxious Duos. Newport International Journal of Research in Medical Sciences (NIJRMS). 2023;3(2):95-99.
72. Ibebuike JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. International Journal of Medical Science and Dental Research, 2018; 1 (2):08-14.https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf.
73. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parametrs in HIV patients before receiving treatment in Aba, Abia State, Nigeria. Res J Pharma Biol Chem Sci. 2014; 5:825-830.
74. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. International Journal of Life Science, Biotechnology and Pharama Research. 2014; 391:186-189.
75. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023; 3 (1): 7-12.
76. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. International Journal of Innovative and Applied Research. 2022;10(5):1-11.

77. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutiase, vitamins C and E in HIV infected children in Umuahia, Abia state. International Journal of Advanced Research in Biological Sciences. 2015;2(11):268-271.
78. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. Newport International Journal of Scientific and Experimental Sciences (NIJSES). 2023;3(2):56-59.
79. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. Int. J. Curr. Res. Med. Sci. 2018;4(2):104-108.
80. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. Int. J. Adv. Res. Biol. Sci. 2018;5(6):60-66.
81. Obeagu EI, Adepoju OJ, Okafor CJ, Obeagu GU, Ibekwe AM, Okpala PU, Agu CC. Assessment of Haematological Changes in Pregnant Women of Ido, Ondo State, Nigeria. J Res Med Dent Sci. 2021;9(4):145-148.
82. Oke OT, Eyitayo EF, Obeagu EI. Inhalation effect of insecticides on some Haematological parameters of rabbits. Int. J. Curr. Res. Chem. Pharm. Sci. 2022;9(9):1-9.
83. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. APPLIED SCIENCES (NIJBAS). 2023;3(3).
84. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-6.
85. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. Arch Blood Transfus Disord. 2018;1(2).
86. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75.
87. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
88. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. Medicine (Baltimore). 2023;102(49): e36599. doi: 10.1097/MD.0000000000036599. PMID: 38065920; PMCID: PMC10713174.
89. Anyiam AF, Arinze-Anyiam OC, Irondi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. Medicine (Baltimore). 2023;102(47): e36342. doi: 10.1097/MD.0000000000036342. PMID: 38013335; PMCID: PMC10681551.
90. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. Medicine (Baltimore). 2023;102(47): e35910. doi: 10.1097/MD.0000000000035910. PMID: 38013350; PMCID: PMC10681510.
91. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. Medicine (Baltimore). 2023;102(46): e36166. doi: 10.1097/MD.0000000000036166. PMID: 37986340; PMCID: PMC10659731.
92. Alum EU, Obeagu EI, Ugwu OPC, Samson AO, Adepoju AO, Amusa MO. Inclusion of nutritional counseling and mental health services in HIV/AIDS management: A paradigm shift. Medicine (Baltimore). 2023;102(41): e35673. doi: 10.1097/MD.0000000000035673. PMID: 37832059; PMCID: PMC10578718.
93. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Sci Rep. 2023;6(8): e1450. doi: 10.1002/hsr2.1450. PMID: 37520460; PMCID: PMC10375546.
94. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. APPLIED SCIENCES (NIJBAS). 2023;3(3).
95. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(11):14-25.
96. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. Int. J. Adv. Multidiscip. Res. 2023;10(10):56-62.
97. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. Newport International Journal of Scientific and Experimental Sciences (NIJSES). 2023;3(2):56-9.

98. Alum EU, Ugwu OP, Obeagu EI, Aja PM, Okon MB, Uti DE. Reducing HIV Infection Rate in Women: A Catalyst to reducing HIV Infection pervasiveness in Africa. International Journal of Innovative and Applied Research. 2023;11(10):01-6.
99. Obeagu EI, Obeagu GU. Unmasking the Truth: Addressing Stigma in the Fight Against HIV. Elite Journal of Public Health. 2024;2(1):8-22.
100. Obeagu EI, Obeagu GU, Okwuanaso CB. Optimizing Immune Health in HIV Patients through Nutrition: A Review. Elite Journal of Immunology. 2024;2(1):14-33.
101. Obeagu EI, Obeagu GU. Utilization of immunological ratios in HIV: Implications for monitoring and therapeutic strategies. Medicine. 2024;103(9):e37354.
102. Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. Elite Journal of Immunology. 2024;2(1):1-3.
103. Obeagu EI, Obeagu GU. Implications of B Lymphocyte Dysfunction in HIV/AIDS. Elite Journal of Immunology. 2024;2(1):34-46.
104. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. Elite Journal of Laboratory Medicine. 2024;2(1):46-58.
105. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. Elite Journal of Medicine. 2024;2(1):35-46.
106. Obeagu EI, Obeagu GU. Platelet-Driven Modulation of HIV: Unraveling Interactions and Implications. Journal home page: http://www. journalijiar. com.;12(01).
107. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. Elite Journal of HIV. 2024;2(1):65-78.
108. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
109. ObeaguEI AA, Obeagu GU. Synergistic Effects of Blood Transfusion and HIV in Children Under 5 Years with Severe Malaria: A Review. Elite Journal of HIV. 2024;2(1):31-50.
110. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. Elite Journal of HIV. 2024;2(1):1-5.
111. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024;10(1):25-36.
112. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. Sciences. 2024;4(1):32-37.
113. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. Sciences. 2024;4(1):38-44.
114. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. Elite Journal of Health Science. 2024;2(1):33-42.
115. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. Elite Journal of Haematology. 2024;2(1):26-41.
116. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between Blood Transfusion and Antiretroviral Medications: Implications for Patient Care. Elite Journal of Medicine. 2024;2(2):104-115.
117. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. Elite Journal of Immunology. 2024;2(1):47-64.
118. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. Elite Journal of HIV. 2024;2(2):1-7.
119. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. Elite Journal of Public Health. 2024;2(1):52-61.
120. Obeagu EI, Obeagu GU. Understanding Hematocrit Fluctuations in HIV-Malaria Coinfection for Improved Management. Elite Journal of Public Health. 2024;2(1):22-34.
121. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. Elite Journal of Nursing and Health Science. 2024;2(1):21-31.
122. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
123. Marincowitz C, Genis A, Goswami N, De Boever P, Nawrot TS, Strijdom H. Vascular endothelial dysfunction in the wake of HIV and ART. The FEBS journal. 2019;286(7):1256-270.

124. Borrajo A, Spuch C, Penedo MA, Olivares JM, Agís-Balboa RC. Important role of microglia in HIV-1 associated neurocognitive disorders and the molecular pathways implicated in its pathogenesis. Annals of Medicine. 2021;53(1):43-69.
125. Hematopoiesis N. Hematologic Manifestations of HIV/AIDS. HIV Curriculum. 2010:222.